Drug intelligence / Profile preview

SR-03

Development stage: Preclinical
Lead developer: Seraxis

Overview

SR-03 is a biological product in preclinical development for the treatment of diabetes mellitus. It was initially developed by Seraxis and is being investigated as a potential therapy within the field of endocrinology and metabolic diseases. While specific mechanistic details are not disclosed, related programs from Seraxis involve pancreatic endocrine cell clusters, suggesting that SR-03 may be an advanced cell-based or regenerative therapy designed to restore insulin production or regulate glucose metabolism in diabetic patients[1][4].

Beyond the preview

Go deeper on SR-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SR-03.

Explore the full profile